Orange County Facility Will Be World’s Largest Producer of Chlorhexidine, a Disinfectant and Antiseptic Vital for Infection Control
$3.8 Million in State Support Will Help Drive Growth in New Windsor and Mid-Hudson Region
Facility to Create 100 High-Skilled Jobs and Expand Global Supply of Critical Antiseptic Products
Project Reinforces New York’s Leadership in Life Sciences, Innovation and Advanced Manufacturing
Governor Kathy Hochul today announced that Garonit Pharmaceutical, Inc., a global manufacturer of antiseptic products and health care solutions, will establish a state-of-the-art, 200,000-square-foot pharmaceutical manufacturing facility in New Windsor, Orange County. With a $46.1 million investment, the facility will become the world’s largest chlorhexidine gluconate manufacturing operation, producing antiseptic products essential for surgical disinfection and infection prevention in hospitals worldwide. New York State is supporting this project with $3.8 million, including up to $3.5 million through the Excelsior Jobs Program and a $300,000 Mid-Hudson Regional Economic Development Council capital grant. The project marks a major milestone in New York’s strategy to grow its life sciences sector and expand domestic pharmaceutical manufacturing.
“New York is leading the way in reshoring pharmaceutical manufacturing, strengthening supply chains and creating high-quality jobs — and Garonit Pharmaceutical’s decision to invest in Orange County is proof of that progress,” Governor Hochul said. “This world-class facility will produce essential antiseptic products used in surgical and hospital settings around the globe, further positioning our state as a leader in the life sciences sector. With this investment, we are not only creating good-paying jobs but also reaffirming that New York is where innovation and opportunity meet.”
Empire State Development President, CEO, and Commissioner Hope Knight said, “Garonit Pharmaceutical’s expansion into New York reflects the confidence that global companies have in our state’s workforce, infrastructure, and innovation ecosystem. The Mid-Hudson region's strategic location, robust infrastructure, and proximity to world-class transportation networks make it an ideal location for advanced manufacturing operations. This project will generate long-term economic benefits and position the region for continued growth in the pharmaceutical sector.”